Previous 10 | Next 10 |
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Jane Pritchett Henderson, previously a member of Sesen Bio’s Board of Directors and the Chair of the Boardȁ...
The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of the BLA. Ahead of the Type A meeting, the burden of proof will be on Sesen’s side to show the efficacy of Vicineum post-2017. ...
3 Penny Stocks to Add to Your Watchlist in Mid-November If you’re looking for penny stocks to buy in 2021, there are plenty of options. But, to have the best chance of making money with penny stocks right now, investors need to understand how the current environment will affe...
3 Penny Stocks to Watch With the Market Taking a Bullish Turn While the market got off to a less than stellar start for both penny stocks and blue chips, by midday, it completely turned around. At around 12:30 PM EST, the Dow Jones and the NASDAQ Composite were up by around 160 points a...
Sesen Bio shares rose (SESN +5.9%) after the company posted third-quarter results and provided an update on its cash position. Net income was $71.7M, or $0.36 per share, for the third quarter of 2021, compared to net loss of $22.6M, or $0.19 per share, for the same period in 2020. The change ...
Sesen Bio (NASDAQ:SESN): Q3 GAAP EPS of $0.36 beats by $0.43. Cash, cash equivalents and restricted cash were $175.3M as of September 30, 2021, compared to $55.4M as of December 31, 2020. Press Release For further details see: Sesen Bio EPS beats by $0.43
Participated in productive CMC Type A Meeting with the FDA Maintained strong balance sheet with $175M in cash and cash equivalents as of September 30, 2021 Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutic...
3 Penny Stocks to Add to Your November Watchlist If you’re making a penny stocks watchlist in November, there are a handful of factors to consider. While we like to think that penny stocks and blue chips trade off of their fundamentals, the majority of the time, speculation i...
Sesen Bio (NASDAQ:SESN) shares rise nearly 2% premarket after conducting a Type A meeting with the U.S. FDA regarding the company's Biologics License Application (BLA) for Vicineum for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. The purpose of the meeting w...
Vicineum™ manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with can...
News, Short Squeeze, Breakout and More Instantly...
Sesen Bio Inc. Company Name:
SESN Stock Symbol:
NASDAQ Market:
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”), today anno...
Sesen Bio Board Believes the Pending Merger with Carisma is the Most Value-Maximizing Option for Stockholders Reiterates Support from Several of Sesen Bio’s Largest Stockholders and Two Leading Independent Proxy Advisors Sesen Bio Board Unanimously Recommends All St...
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis’s Recommendations to Vote “FOR” Value Maximizing Merger on WHITE ...